Could a common antifungal improve Crohn's therapy?

NCT ID NCT06274554

Recruiting now Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether adding the antifungal drug fluconazole to standard IL-23 therapy helps people with mild to moderate Crohn's disease. About 120 adults will be randomly assigned to receive either fluconazole or a placebo alongside their usual treatment. The main goal is to see if more people achieve a significant reduction in symptoms after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fluconazole (an antifungal drug) added to standard IL-23 therapy (risankizumab, guselkumab, or ustekinumab)
What this could lead to: If it works, this could point toward a way to make existing Crohn's treatments more effective by targeting gut fungi.
What could go wrong: This is a phase 3 trial, but it's still relatively small (120 people) and the benefit of adding an antifungal is unproven. Fluconazole can cause liver issues and drug interactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN'S DISEASE INFLAMMATORY BOWEL DISEASES

Contacts and locations

Locations

Weill Cornell Medicine
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.